Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels

Creative Commons License

SASSİ A., LAZAROSKİ S., WU G., HASLAM S. M., FLIEGAUF M., MELLOULI F., ...More

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol.133, no.5, pp.1410-1432, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 133 Issue: 5
  • Publication Date: 2014
  • Doi Number: 10.1016/j.jaci.2014.02.025
  • Journal Name: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1410-1432
  • Keywords: Hyper-IgE syndrome, glycosylation, Staphylococcus aureus, signal transducer and activator of transcription 3, dedicator of cytokinesis 8, phosphoglucomutase 3, CONGENITAL DISORDERS, GLYCOSYLATION, DEFICIENCY, MUTASE, DOCK8, IDENTIFICATION, CLONING, DESIGN, PROBES, STAT3
  • Erciyes University Affiliated: Yes

Abstract

Background: Recurrent bacterial and fungal infections, eczema, and increased serum IgE levels characterize patients with the hyper-IgE syndrome (HIES). Known genetic causes for HIES are mutations in signal transducer and activator of transcription 3 (STAT3) and dedicator of cytokinesis 8 (DOCK8), which are involved in signal transduction pathways. However, glycosylation defects have not been described in patients with HIES. One crucial enzyme in the glycosylation pathway is phosphoglucomutase 3 (PGM3), which catalyzes a key step in the synthesis of uridine diphosphate N-acetylglucosamine, which is required for the biosynthesis of N-glycans.